
|Articles|January 1, 2004
FDA approves first accommodative IOL
Cataract surgeons who participated in the premarketing clinical trials for the model AT-45 accommodative IOL (Crystalens, eyeonics inc. [formerly C&C Vision]) are heralding that technology as an important advance. The lens affords patients clear uncorrected vision at near, intermediate, and distance. FDA approval for marketing of the lens was granted in November.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approvals in 2025: What changed and why it matters for ophthalmologists
2
Achieving a new level of refractive precision: Surgical strategies
3
What changed in glaucoma care in 2025: Surgeon perspective
4
Global trial equity: How LMIC data is reshaping US ophthalmology research
5




